HCoV VACCINE FOR IMPROVING IMMUNITY AGAINST SARS-COV-2 INFECTION

Abstract

Embodiments include a method of using inactivated human cold coronaviruses (HCoVs) particularly HCoV-299E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1, alone or as a booster, for the immunization against SARS-CoV-2 infections. Vaccine embodiments further comprise HCoV virus envelope subunits which may be in the form of virus-like spheroids (VLS).

1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . (canceled) 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . (canceled) 
     
     
         23 . (canceled) 
     
     
         24 . (canceled) 
     
     
         25 . (canceled) 
     
     
         26 . (canceled) 
     
     
         27 . (canceled) 
     
     
         28 . (canceled) 
     
     
         29 . (canceled) 
     
     
         31 . (canceled) 
     
     
         32 . (canceled) 
     
     
         33 . (canceled) 
     
     
         34 . An immunogenic composition comprising lipid virus-like spheroid particles wherein the virus like spheroid particles comprise immunogenic protein epitopes associated with glycoprotein spikes in the lipid membrane from HCoV-NL63 and HCoV-HKU 1  and the lipid virus-like spheroid particles contain less immunogenic protein epitopes than associated with the full native virus selected, and the lipid virus-like spheroid particles are formed by: (a) selecting copper foam with a copper skeleton of pores around 50 μm; (b) immersing a portion of the copper foam into an aqueous solution of 0.03 M AgNO3 at room temperature; (c) treating the immersed silver foam with a mixed ethanol solution containing HS(CH 2 ) 11 CH 3  and HS(CH 2 ) 10 COOH to form a treated copper foam; (d) drying the treated copper foam to form the final treated copper foam (FTCF); (e) running enveloped virus of HCoV-NL63 and HCoV-HKU1_ separately through untreated copper foam followed by the treated copper foam in a pH 7-7.4 solution; (f) releasing materials captured by the final treated copper foam by directing solution with a pH of 10.5-11 over said final treated foam; (g) separating out spheroids having a diameter between 90-150 nm. 
     
     
         35 . The immunogenic composition of  claim 34  further comprising an adjuvant from one at least of: alum, algammulin, monophosphoryl lipid A (MPL), resiquimod, muramyl dipeptide (MPD), N glycolyl dipeptide (GMDP), polyIC, CpG oligonucleotide, aluminum salts, water-in-oil emulsion and oil-in-water emulsion. 
     
     
         36 . The immunogenic composition of  claim 35  comprising an resiquimod adjuvant. 
     
     
         37 . The immunogenic composition of  claim 35  comprising an aluminum salt adjuvant. 
     
     
         38 . The immunogenic composition of  claim 35  comprising an alum adjuvant. 
     
     
         39 . The immunogenic composition of  claim 35  comprising a muramyl dipeptide adjuvant. 
     
     
         40 . The immunogenic composition of  claim 35  comprising an algammulin adjuvant. 
     
     
         41 . The immunogenic composition of  claim 35  a monophosphoryl lipid A adjuvant. 
     
     
         42 . The immunogenic composition of  claim 35  comprising N glycolyl dipeptide adjuvant. 
     
     
         43 . The immunogenic composition of  claim 35  comprising polyIC adjuvant. 
     
     
         44 . The immunogenic composition of  claim 35  comprising CpG oligonucleotide adjuvant. 
     
     
         45 . The immunogenic composition of  claim 35  comprising water-in-oil emulsion adjuvant. 
     
     
         46 . The immunogenic composition of  claim 35  comprising oil-in-water emulsion adjuvant. 
     
     
         47 . The immunogenic composition of  claim 35  comprising alum and MPD adjuvant.